275 related articles for article (PubMed ID: 22644033)
1. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.
Miró JM; Entenza JM; Del Río A; Velasco M; Castañeda X; Garcia de la Mària C; Giddey M; Armero Y; Pericàs JM; Cervera C; Mestres CA; Almela M; Falces C; Marco F; Moreillon P; Moreno A;
Antimicrob Agents Chemother; 2012 Aug; 56(8):4511-5. PubMed ID: 22644033
[TBL] [Abstract][Full Text] [Related]
2. Emerging issues on
García de la Mària C; Cañas MA; Fernández-Pittol M; Dahl A; García-González J; Hernández-Meneses M; Cuervo G; Moreno A; Miró JM; Marco F
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):281-293. PubMed ID: 36744387
[TBL] [Abstract][Full Text] [Related]
3. The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis.
García-de-la-Mària C; Gasch O; García-Gonzalez J; Soy D; Shaw E; Ambrosioni J; Almela M; Pericàs JM; Tellez A; Falces C; Hernandez-Meneses M; Sandoval E; Quintana E; Vidal B; Tolosana JM; Fuster D; Llopis J; Pujol M; Moreno A; Marco F; Miró JM
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610194
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.
Duss FR; Garcia de la Mària C; Croxatto A; Giulieri S; Lamoth F; Manuel O; Miró JM
J Antimicrob Chemother; 2019 Sep; 74(9):2626-2630. PubMed ID: 31298264
[TBL] [Abstract][Full Text] [Related]
5. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
Xiong YQ; Hady WA; Bayer AS; Chen L; Kreiswirth BN; Yang SJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5528-33. PubMed ID: 22890759
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial.
del Río A; Gasch O; Moreno A; Peña C; Cuquet J; Soy D; Mestres CA; Suárez C; Pare JC; Tubau F; Garcia de la Mària C; Marco F; Carratalà J; Gatell JM; Gudiol F; Miró JM;
Clin Infect Dis; 2014 Oct; 59(8):1105-12. PubMed ID: 25048851
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Jacqueline C; Amador G; Batard E; Le Mabecque V; Miègeville AF; Biek D; Caillon J; Potel G
J Antimicrob Chemother; 2011 Apr; 66(4):863-6. PubMed ID: 21393213
[TBL] [Abstract][Full Text] [Related]
8. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Marco F; de la Mària CG; Armero Y; Amat E; Soy D; Moreno A; del Río A; Almela M; Mestres CA; Gatell JM; Jiménez de Anta MT; Miró JM;
Antimicrob Agents Chemother; 2008 Jul; 52(7):2538-43. PubMed ID: 18426900
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
[TBL] [Abstract][Full Text] [Related]
10. Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.
del Río A; García-de-la-Mària C; Entenza JM; Gasch O; Armero Y; Soy D; Mestres CA; Pericás JM; Falces C; Ninot S; Almela M; Cervera C; Gatell JM; Moreno A; Moreillon P; Marco F; Miró JM;
Antimicrob Agents Chemother; 2016 Jan; 60(1):478-86. PubMed ID: 26525803
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Sakoulas G; Eliopoulos GM; Alder J; Eliopoulos CT
Antimicrob Agents Chemother; 2003 May; 47(5):1714-8. PubMed ID: 12709345
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE).
Cunha BA; Pherez FM
Eur J Clin Microbiol Infect Dis; 2009 Jul; 28(7):831-3. PubMed ID: 19184141
[TBL] [Abstract][Full Text] [Related]
13. In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis.
Dortet L; Anguel N; Fortineau N; Richard C; Nordmann P
Int J Infect Dis; 2013 Nov; 17(11):e1076-7. PubMed ID: 23578850
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Fernandez J; Abbanat D; Shang W; He W; Amsler K; Hastings J; Queenan AM; Melton JL; Barron AM; Flamm RK; Lynch AS
Antimicrob Agents Chemother; 2012 Mar; 56(3):1476-84. PubMed ID: 22232278
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis.
Castañeda X; García-De-la-Mària C; Gasch O; Pericàs JM; Soy D; Cañas-Pacheco MA; Falces C; García-González J; Hernández-Meneses M; Vidal B; Almela M; Quintana E; Tolosana JM; Fuster D; Llopis J; Dahl A; Moreno A; Marco F; Miró JM;
J Antimicrob Chemother; 2021 May; 76(6):1539-1546. PubMed ID: 33837406
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.
Huang DB; Gaukel E; Kerzee N; Borroto-Esoda K; Lowry S; Xiong YQ; Abdelhady W; Bayer AS
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0050821. PubMed ID: 34097491
[TBL] [Abstract][Full Text] [Related]
17. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
18. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report.
Chen LY; Huang CH; Kuo SC; Hsiao CY; Lin ML; Wang FD; Fung CP
BMC Infect Dis; 2011 May; 11():152. PubMed ID: 21612672
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Steed ME; Werth BJ; Ireland CE; Rybak MJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5709-14. PubMed ID: 22908167
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Rose WE; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
